Literature DB >> 12714514

Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study.

Alfonso Mele1, Alessandro Pulsoni, Elvira Bianco, Pellegrino Musto, Andre Szklo, Maria Grazia Sanpaolo, Emilio Iannitto, Amalia De Renzo, Bruno Martino, Vincenzo Liso, Cristina Andrizzi, Simona Pusterla, Fausto Dore, Maddalena Maresca, Maria Rapicetta, Fabrizio Marcucci, Franco Mandelli, Silvia Franceschi.   

Abstract

The existence of an association between infection with hepatitis C virus (HCV) and B-cell non-Hodgkin lymphoma (B-NHL) remains controversial, largely because previous studies were based on prevalent case series or comparisons with less than optimal control groups. This hospital-based case-control study was conducted from January 1998 through February 2001 to evaluate the association between HCV infection and B-NHL of different types. Cases were consecutive patients with a new diagnosis of B-NHL; controls were patients from other departments of the same hospitals. Both groups were interviewed using a standardized questionnaire. The prevalence of HCV infection was calculated by histologic type of B-NHL and clinical behavior (indolent or aggressive). Adjusted odds ratio (OR) and HCV-attributable risk (AR) were estimated. HCV prevalence was 17.5% among the 400 lymphoma patients and 5.6% among the 396 controls. The OR of B-NHL (patients vs controls), adjusted by age, sex, level of education, and place of birth, was 3.1 (95% confidence interval [CI], 1.8-5.2); an OR indicative of positive association was found for indolent and aggressive B-NHL. The estimated AR was 4.6%. This study confirms an association between HCV and B-NHL. In Italy, 1 of 20 instances of B-NHL may be attributable to HCV infection and may, thus, benefit from antiviral treatment.

Entities:  

Mesh:

Year:  2003        PMID: 12714514     DOI: 10.1182/blood-2002-10-3230

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  62 in total

1.  Investigation of residual hepatitis C virus in presumed recovered subjects.

Authors:  Kei Fujiwara; Robert D Allison; Richard Y Wang; Patricia Bare; Kentaro Matsuura; Cathy Schechterly; Krishna Murthy; Francesco M Marincola; Harvey J Alter
Journal:  Hepatology       Date:  2012-12-06       Impact factor: 17.425

2.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.

Authors:  Souichi Shiratori; Yutaka Tsutsumi; Takahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Nobuo Masauzi; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2008-03-06       Impact factor: 2.490

Review 4.  Hepatitis viruses and non-Hodgkin's lymphoma: A review.

Authors:  Sibnarayan Datta; Soumya Chatterjee; Rudragoud S Policegoudra; Hemant K Gogoi; Lokendra Singh
Journal:  World J Virol       Date:  2012-12-12

5.  Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi.

Authors:  Michele Merli; Carlo Visco; Michele Spina; Stefano Luminari; Virginia Valeria Ferretti; Manuel Gotti; Sara Rattotti; Valeria Fiaccadori; Chiara Rusconi; Clara Targhetta; Caterina Stelitano; Alessandro Levis; Achille Ambrosetti; Davide Rossi; Luigi Rigacci; Alfonso Maria D'Arco; Pellegrino Musto; Annalisa Chiappella; Luca Baldini; Maurizio Bonfichi; Luca Arcaini
Journal:  Haematologica       Date:  2013-11-22       Impact factor: 9.941

6.  Regression of B-cell lymphoma of the liver with hepatitis C virus infection after treatment with pegylated interferon-alpha and ribavirin.

Authors:  Yayoi Oda; Tadayuki Kou; Masaki Watanabe; Yojiro Sakuma; Nori Taguchi; Yoko Kato; Yasushi Kudo; Atsushi Yamauchi; Yasushi Sugiura; Shinya Ohashi; Masanori Asada; Toyokazu Fukunaga; Kiyotaka Kawaguchi; Hiroaki Ito; Takefumi Nakamura; Shujiro Yazumi
Journal:  Dig Dis Sci       Date:  2009-08-06       Impact factor: 3.199

7.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

8.  Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Authors:  Therese Högfeldt; Crystal Jaing; Kevin Mc Loughlin; James Thissen; Shea Gardner; Abeer A Bahnassy; Baback Gharizadeh; Joachim Lundahl; Anders Österborg; Anna Porwit; Abdel-Rahman N Zekri; Hussein M Khaled; Håkan Mellstedt; Ali Moshfegh
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

9.  Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium.

Authors:  Silvia de Sanjose; Yolanda Benavente; Claire M Vajdic; Eric A Engels; Lindsay M Morton; Paige M Bracci; John J Spinelli; Tongzhang Zheng; Yawei Zhang; Silvia Franceschi; Renato Talamini; Elizabeth A Holly; Andrew E Grulich; James R Cerhan; Patricia Hartge; Wendy Cozen; Paolo Boffetta; Paul Brennan; Marc Maynadié; Pierluigi Cocco; Ramon Bosch; Lenka Foretova; Anthony Staines; Nikolaus Becker; Alexandra Nieters
Journal:  Clin Gastroenterol Hepatol       Date:  2008-04       Impact factor: 11.382

10.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.